Clinical Trials Logo

Meningeal Carcinomatosis clinical trials

View clinical trials related to Meningeal Carcinomatosis.

Filter by:

NCT ID: NCT00515788 Terminated - Clinical trials for Neoplastic Meningitis

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Start date: February 2006
Phase: Phase 1
Study type: Interventional

Objectives: - To determine the safety, tolerability and maximum tolerated dose (MTD) of oral temozolomide using a 7 days on and 7 days off regimen combined with intrathecal liposomal cytarabine (DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic lymphoma.

NCT ID: NCT00512460 Terminated - Lymphoma Clinical Trials

RTA 744 Injection in Patients With Leptomeningeal Disease

Start date: September 2006
Phase: Phase 1
Study type: Interventional

1. The primary objectives of this study are: 1. To determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor. 2. In a selected group of 6-10 patients who will receive RTA 744 at or near the maximum tolerated dose (MTD), to characterize the multiple-dose pharmacokinetics of RTA 744 in plasma and CSF. 2. The secondary objectives of this study are: 1. To document any potential antitumor activity of RTA 744 in this patient population. 2. To correlate pharmacokinetic information with clinical (efficacy and safety) responses, as a possible help in selecting appropriate doses for later studies.

NCT ID: NCT00112619 Terminated - Lymphoma Clinical Trials

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Start date: August 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of topotecan when given by intraventricular infusion in treating young patients with neoplastic meningitis due to leukemia, lymphoma, or solid tumors.

NCT ID: NCT00074607 Terminated - Neoplasms Clinical Trials

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Subject's are being asked to take part in this study because he or she has a type of cancer that has spread to the meninges (tissues that cover the brain and spinal cord). There is no known effective treatment for this specific disease or the subject has received all of the treatments that are known to work for his or her specific disease without success. Currently, there is no other effective treatment for this type of cancer. The purposes of this study are: - to determine the highest dose of gemcitabine, an anti-cancer drug, that can safely be given directly into the spinal fluid of children and adults whose cancer no longer responds to standard treatment; - to find out what effects (good and bad) gemcitabine has when given directly into the cerebrospinal fluid (called intrathecal administration) in children and adults with neoplastic meningitis (cancer that has spread to the lining of the brain and spinal cord); - to determine if gemcitabine is beneficial to the patient; - to understand how gemcitabine is handled by the body after intrathecal administration.

NCT ID: NCT00005812 Terminated - Brain Tumors Clinical Trials

Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

Start date: January 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have leptomeningeal metastases from a solid tumor or lymphoma.